The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.

Q2 Medicine Asian Pacific Journal of Cancer Prevention Pub Date : 2025-01-01 DOI:10.31557/APJCP.2025.26.1.23

Marzieh Haghbin, Abdolreza Sotoodeh Jahromi, Akbar Hashemi Tayer, Zahra Ghasemi Nejad

{"title":"The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.","authors":"Marzieh Haghbin, Abdolreza Sotoodeh Jahromi, Akbar Hashemi Tayer, Zahra Ghasemi Nejad","doi":"10.31557/APJCP.2025.26.1.23","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BC) is a global challenge that affects a large portion of individuals, especially women. It has been suggested that microparticles (MPs) can be used as a diagnostic, prognostic, or therapeutic biomarker in various diseases. Moreover, MPs are known to elevate in cancer cases. Platelet-derived MPs (PMPs) play a crucial role in the metastasis of BC, warranting specific focus. This study aimed to explore the involvement of procoagulant MPs in BC.Methods: This systematic review was carried out using the Preferred Reporting Items for Systematic reviews, and Meta-Analyses (PRISMA). Terms defined as MESH keywords were searched PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library searched in from 2011 to March 2024. Experimental and quasi-experimental studies were assessed by the CONSORT checklist.Results: Eventually, 15 studies were included. 426 participants were studied in the included articles. The potential clinical relevance of MPs as biomarkers in BC was indicated. Also, the role of MPs in immune modulation and multidrug resistance was approved. PMPs were found to enhance malignant features, including migration and invasion. Moreover, there were lower levels of MPs before neo-adjuvant chemotherapy, suggesting a potential impact of chemotherapy on MPs levels. The study highlights the remarkable capacity of multidrug-resistant BC-derived MPs to alter the phenotype and functionality of immune cells.Conclusions: The findings underscore the intricate interplay between MPs and cellular signaling pathways, shedding light on their potential as diagnostic biomarkers, and therapeutic targets in cancer. Specifically, the association between MPs levels and disease severity, as evidenced by their correlation with tissue-based biomarkers, tumor grading, and distant metastasis, highlights their clinical relevance in prognostication and risk stratification.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 1","pages":"23-32"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082420/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.1.23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer (BC) is a global challenge that affects a large portion of individuals, especially women. It has been suggested that microparticles (MPs) can be used as a diagnostic, prognostic, or therapeutic biomarker in various diseases. Moreover, MPs are known to elevate in cancer cases. Platelet-derived MPs (PMPs) play a crucial role in the metastasis of BC, warranting specific focus. This study aimed to explore the involvement of procoagulant MPs in BC.

Methods: This systematic review was carried out using the Preferred Reporting Items for Systematic reviews, and Meta-Analyses (PRISMA). Terms defined as MESH keywords were searched PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library searched in from 2011 to March 2024. Experimental and quasi-experimental studies were assessed by the CONSORT checklist.

Results: Eventually, 15 studies were included. 426 participants were studied in the included articles. The potential clinical relevance of MPs as biomarkers in BC was indicated. Also, the role of MPs in immune modulation and multidrug resistance was approved. PMPs were found to enhance malignant features, including migration and invasion. Moreover, there were lower levels of MPs before neo-adjuvant chemotherapy, suggesting a potential impact of chemotherapy on MPs levels. The study highlights the remarkable capacity of multidrug-resistant BC-derived MPs to alter the phenotype and functionality of immune cells.

Conclusions: The findings underscore the intricate interplay between MPs and cellular signaling pathways, shedding light on their potential as diagnostic biomarkers, and therapeutic targets in cancer. Specifically, the association between MPs levels and disease severity, as evidenced by their correlation with tissue-based biomarkers, tumor grading, and distant metastasis, highlights their clinical relevance in prognostication and risk stratification.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

促凝微粒作为乳腺癌血液凝固生物标志物的潜在临床意义：系统综述。

背景：乳腺癌（BC）是一个全球性的挑战，影响了很大一部分人，尤其是女性。已有研究表明，微颗粒（MPs）可作为多种疾病的诊断、预后或治疗性生物标志物。此外，众所周知，MPs在癌症病例中会升高。血小板来源的MPs （pmp）在BC的转移中起着至关重要的作用，需要特别关注。本研究旨在探讨促凝剂MPs在BC中的作用。方法：本系统评价采用首选报告项目进行系统评价和meta分析（PRISMA）。从2011年到2024年3月，检索了PubMed/MEDLINE、Embase、Web of Science和Cochrane Library中定义为MESH关键字的术语。实验和准实验研究通过CONSORT检查表进行评估。结果：最终纳入了15项研究。纳入的文章对426名参与者进行了研究。MPs作为BC的生物标志物具有潜在的临床意义。此外，MPs在免疫调节和多药耐药中的作用也得到了证实。发现pmp增强了恶性特征，包括迁移和侵袭。此外，新辅助化疗前MPs水平较低，提示化疗对MPs水平有潜在影响。该研究强调了多药耐药bc衍生MPs改变免疫细胞表型和功能的显着能力。结论：这些发现强调了MPs和细胞信号通路之间复杂的相互作用，揭示了它们作为癌症诊断生物标志物和治疗靶点的潜力。具体而言，MPs水平与疾病严重程度之间的关联，与基于组织的生物标志物、肿瘤分级和远处转移的相关性证明了它们与预后和风险分层的临床相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.